Zimmer Biomet Holdings, Inc. (SWX:ZBH)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 12.52B -24.6% |
| Revenue (ttm) | 6.75B +9.2% |
| Net Income | 610.57M -16.7% |
| EPS | 3.09 -14.4% |
| Shares Out | n/a |
| PE Ratio | 20.51 |
| Forward PE | 9.74 |
| Dividend | 0.77 (1.21%) |
| Ex-Dividend Date | Mar 31, 2026 |
| Volume | 4 |
| Average Volume | 59 |
| Open | 65.00 |
| Previous Close | 63.50 |
| Day's Range | 65.00 - 65.00 |
| 52-Week Range | 62.50 - 119.00 |
| Beta | 1.01 |
| RSI | 36.39 |
| Earnings Date | Apr 28, 2026 |
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well a... [Read more]
Financial Performance
In 2025, Zimmer Biomet Holdings's revenue was $8.23 billion, an increase of 7.20% compared to the previous year's $7.68 billion. Earnings were $705.10 million, a decrease of -21.98%.
Financial numbers in USD Financial StatementsNews
Zimmer Biomet Holdings Transcript: Bank of America Global Healthcare Conference 2026
Q1 2026 delivered strong organic growth, led by technology and international markets, while U.S. knees underperformed but are expected to recover. Major product launches and a dedicated sales force transformation are underway, with robust innovation and integration of recent acquisitions supporting future growth.
Zimmer Biomet increases share repurchase program by $250M
Zimmer Biomet (ZBH) announced that it now anticipates repurchasing up to $1B of its common stock during fiscal year 2026, a $250M increase from the company’s prior assumption. Published first…
Zimmer Biomet Increases Share Repurchase Expectations -- Up to $1 Billion by Year End
WARSAW, Ind., May 12, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it now anticipates repurchasing up to $1 billion o...
Zimmer Biomet to Present at the BofA Securities 2026 Health Care Conference
WARSAW, Ind., May 6, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will p...
Zimmer Biomet price target lowered to $92 from $98 at Truist
Truist lowered the firm’s price target on Zimmer Biomet (ZBH) to $92 from $98 and keeps a Hold rating on the shares. The company delivered 2.9% organic revenue growth in…
Zimmer Biomet price target lowered to $95 from $100 at JPMorgan
JPMorgan lowered the firm’s price target on Zimmer Biomet (ZBH) to $95 from $100 and keeps a Neutral rating on the shares.
Zimmer Biomet price target lowered to $105 from $110 at Stifel
Stifel analyst Rick Wise lowered the firm’s price target on Zimmer Biomet (ZBH) to $105 from $110 and keeps a Buy rating on the shares.
Zimmer Biomet price target lowered to $83 from $93 at Canaccord
Canaccord lowered the firm’s price target on Zimmer Biomet (ZBH) to $83 from $93 and keeps a Buy rating on the shares. The firm said they delivered a solid Q1…
Zimmer Biomet price target lowered to $92 from $100 at Baird
Baird lowered the firm’s price target on Zimmer Biomet (ZBH) to $92 from $100 and keeps a Neutral rating on the shares. The firm updated its model ahead of Q1…
Zimmer Biomet price target lowered to $95 from $98 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Zimmer Biomet (ZBH) to $95 from $98 and keeps a Neutral rating on the shares.
Zimmer Biomet price target lowered to $105 from $120 at Citizens
Citizens lowered the firm’s price target on Zimmer Biomet (ZBH) to $105 from $120 and keeps an Outperform rating on the shares. Zimmer Biomet delivered a modest revenue beat and…
Zimmer Biomet price target lowered to $94 from $100 at Barclays
Barclays analyst Matt Miksic lowered the firm’s price target on Zimmer Biomet (ZBH) to $94 from $100 and keeps an Underweight rating on the shares. The firm says the company’s…
Zimmer Biomet Holdings Earnings Call Transcript: Q1 2026
Sales and EPS exceeded expectations, driven by strong technology adoption and new product launches, with guidance for EPS and free cash flow raised for 2026. Strategic investments and sales force transformation are progressing, while recent acquisitions accelerate growth.
Medical device maker Zimmer Biomet raises annual profit forecast, announces CFO departure
Zimmer Biomet on Tuesday raised its 2026 adjusted profit forecast after reporting better-than-expected quarterly results, helped by strong demand for its medical devices and new product launches.
Zimmer Biomet CFO Suketu Upadhyay to depart
Zimmer Biomet (ZBH) announced Suketu Upadhyay, CFO and executive VP, finance, operations and supply chain, will depart the company effective April 28 for a new professional opportunity. The company ha...
Zimmer Biomet Announces First Quarter 2026 Financial Results
First quarter net sales of $2.087 billion increased 9.3% on a reported basis, 6.8% on a constant currency1 basis and 2.9% on an organic constant currency1 basis First quarter diluted earnings per shar...
Zimmer Biomet Announces Chief Financial Officer Transition
Suketu Upadhyay to Depart; Paul Stellato Named Interim CFO WARSAW, Ind., April 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today anno...
Zimmer Biomet initiated with a Market Perform at Leerink
Leerink initiated coverage of Zimmer Biomet (ZBH) with a Market Perform rating and $10 price target While the shares are trading at a discount to its large-cap medical technology peers…
Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2026 Financial Results
WARSAW, Ind., April 9, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its first quarter earnings conference call will be web...
Zimmer Biomet names new Chief Science, Technology and Medical Affairs Officer
Zimmer Biomet (ZBH) appointed Jonathan Vigdorchik as Chief Science, Technology and Medical Affairs Officer, effective April 14. In this role, Vigdorchik will oversee the strategy, delivery, and manage...
Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer
Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company in an elevated capacity WARSAW, Ind., April 7, 2026 /PRNewswir...
Zimmer Biomet Holdings, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, March 06, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Zimmer Biomet Holdings, Inc., (“Zimmer" or the "Company") (NYSE:ZBH) investors that the firm has initiated an investigation...
Zimmer Biomet to Release New Data, Highlight Key Innovations at American Academy of Orthopaedic Surgeons Annual Meeting
Company's Chief Movement Officer, Arnold Schwarzenegger,Will Be Presidential Guest Speaker WARSAW, Ind., Feb. 25, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medica...
Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2026
WARSAW, Ind., Feb. 23, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment o...
Zimmer Biomet Holdings Earnings Call Transcript: Q4 2025
Q4 2025 saw 5.4% organic sales growth and strong U.S. performance, with new products and robotics driving results. 2026 guidance anticipates 1%-3% revenue growth and continued Salesforce transformation, with short-term disruption but long-term productivity gains expected.